Every year near 100,000 kids worldwide die of cancer, largely because of the lack of innovative treatments for the types of cancer affecting children and adolescents. Oncoheroes Biosciences, has built a multi-asset portfolio of drugs to potentially treat several types of childhood cancer that have had little significant improvement over the past 20-30 years in overall survival.
“We are passionate about cancer research combined with a sense of urgency. We have been researching Oncoheroes’ lead compound, volasertib, for several years and feel confident in its efficacy”, said Christina Stiverson, President of the Foundation for Addie’s Research. “The foundation is extremely excited to support Oncoheroes moving volasertib into a clinical trial to create more and better options for children fighting cancer. This effort could have made a difference for my daughter Addie who ran out of available treatments”.
Adelaide “Addie” was a childhood cancer warrior who lost her battle with Hepatoblastoma in 2016 at the age of three. Foundation for Addie’s Research is focused on pre-clinical research and innovative trials to create more options for children like Addie.
In addition, Foundation for Addie’s Research created the Hepatoblastoma Resource Network, a credible consolidated resource for families, to unite a fractured rare cancer community. “Last year we spearheaded the first ever virtual global conference bringing together researchers, clinicians, and parents from 18 different countries!” added Christina Stiverson, President of the Foundation for Addie’s Research.
“We are encouraged by preclinical data showing volasertib could be used for other cancer indications beyond rhabdomyosarcoma, our initial planned trial. We are working with academic centers worldwide to explore other indications like DIPG, Ewing sarcoma, medulloblastoma, neuroblastoma and hepatoblastoma”, stated Cesare Spadoni, Co-Founder and COO of Oncoheroes Biosciences. ”We welcome Foundation for Addie’s Research to Oncoheroes and are excited to get aligned for the benefit of hepatoblastoma patients. Thank you, Foundation for Addie’s Research.”
